Focal Point Pharmaceuticals
2013
FOUNDED
PRIVATE
STATUS
Early Stage VC
LATEST DEAL TYPE
$80K
LATEST DEAL AMOUNT
1
INVESTORS
Description
Developer of products designed to treat ocular diseases. The company's products are developed with pre-clinical research and lead selection, enabling clients to treat rare diseases, including ocular trauma and other eye diseases.
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
- 40 South Main Street
- Suite 2300
- Memphis, TN 38103
- United States
+1 (484) 000-0000
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore Focal Point Pharmaceuticals’s full profile, request a free trial.
Focal Point Pharmaceuticals Valuation and Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Early Stage VC | 31-Jan-2017 | $80K | 00000 | Completed | Generating Revenue | |
| 2. Early Stage VC | 14-Aug-2013 | 00000 | 00000 | Completed | Generating Revenue | |
| 1. Grant | Completed | Generating Revenue |
Focal Point Pharmaceuticals Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Board Seat |
Contact Info |
|---|---|---|---|---|---|---|
| MB Venture Partners | Venture Capital | Minority | 000 0000 | 000000 0 |
Focal Point Pharmaceuticals Executive Team (3)
| Name | Title | Board Seat |
Contact Info |
|---|---|---|---|
| Edward Chaum MD | Co-Founder & Chief Scientific Officer | ||
| Gary Prosterman | Treasurer & Board Member | ||
| Raymond Hage Jr. | President & Board Member |
Focal Point Pharmaceuticals Board Members (3)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| Gary Prosterman | Focal Point Pharmaceuticals | Treasurer & Board Member | 000 0000 | |
| Gary Stevenson | MB Venture Partners | Board Member | 000 0000 | |
| Raymond Hage Jr. | Self | President & Board Member | 000 0000 |